MktsMarkets

Enveric Biosciences, Inc.
NASDAQ: ENVBKey statistics
ENVB News
Stories mentioning ENVB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 346.00 | 373.00 | 402.00 | 1,260 | 746.00 | 967.00 | 803.00 | 565.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (1,633) | (2,193) | (1,874) | (2,519) | (2,188) | (3,174) | (2,083) | (1,898) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (1.00) | |||||||
| Pretax Income | (1,633) | (2,194) | (1,874) | (2,519) | (2,185) | (3,148) | (2,084) | (1,879) |
| Tax Provision | ||||||||
| Net Income (Loss) | (1,633) | (2,194) | (1,874) | (2,519) | (2,185) | (3,155) | (2,084) | (1,879) |
| Earnings Per Share (Basic) | (1.08) | (6.55) | (10.81) | (0.97) | (14.58) | (75.12) | (43.10) | (3.72) |
| Earnings Per Share (Diluted) | (1.08) | (6.55) | (10.81) | (0.97) | (14.58) | (75.12) | (43.10) | (3.72) |
| Weighted Average Shares Outstanding (Basic) | 1,510 | 335.00 | 313.00 | 2,596 | 150.00 | 42.00 | 48.00 | 506.00 |
| Weighted Average Shares Outstanding (Diluted) | 1,510 | 335.00 | 313.00 | 2,596 | 150.00 | 42.00 | 48.00 | 506.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ENVB
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a stock listed on the Nasdaq Stock Market under the ticker symbol ENVB. It last traded at $1.35 (Nov 20, 2026, 4:00 PM ET), down 4.3% on the day. That gives Enveric Biosciences a market capitalisation of $6.0M.
Over the past 52 weeks ENVB has traded between $1.17 and $13.25.
For the quarter ended Mar 31, 2026 it reported a net loss of $1.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$1.6M |
| Dec 31, 2025 | — | -$2.2M |
| Sep 30, 2025 | — | -$1.9M |
| Jun 30, 2025 | — | -$2.5M |
From Enveric Biosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…